The Pharmaceutical Market: Norway

Espicom Healthcare Intelligence
May 15, 2012
74 Pages - SKU: ESPI3909419
Countries covered: Norway

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.

Specialised intelligence on OTCs, generics, biologics and biosimilars.

Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.

A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.

The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

Please Note: this is delivered as a Zip file.


Additional Information

THE PHARMACEUTICAL MARKET: NORWAY - REVIEW

The macroenvironment for the Norwegian pharmaceutical industry is improving. Politically, the centre-left coalition is expected to hold together at least until the general election in September 2013, but the risk of the coalition breaking up has grown. Economically, the recession was far less pronounced in Norway than in most other European countries and economic recovery is now strengthening. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. However, Norway remains on the USTR’s Watch List in 2011 for concerns over patent protection. Demographically, the population is ageing, increasing demand for pharmaceuticals in the near term.

The introduction of international reference pricing has had a moderating effect on Norwegian pharmaceutical price levels, and a step-price system for off-patent drugs has ensured that prices for all generics have fallen. Important steps towards cost-containment have also been taken for reimbursable pharmaceuticals, including the use of a first-choice system. A report by the Business Research Foundation (SNF) has shown that Norwegian pharmaceutical prices are among the lowest in Western Europe. Therefore, market growth is a result of increased consumption, largely due to the ageing population and the introduction of new drugs on the market. Norway is receptive to new drugs, as long as they are cost-effective and have proven therapeutic benefits.

Although Norway is not part of the European Union, the process for pharmaceutical registration has been aligned to EU regulations. The regulatory reforms made the centralised procedure mandatory for all new active substances, and all drugs in a number of drug categories, including all biotech products. In May 2011, PCI Biotech reported that it had been awarded a BIA grant from the Research Council of Norway for the project “immunological effects of photochemical internalisation – local treatment of cancer with metastasis”. The project was initiated in the third quarter of 2011, and will run for three years.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.




More Information...

HIGHLY DETAILED REPORT CONTENT

EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections

MACROENVIRONMENT
Political, economic, legal and demographic analysis

EPIDEMIOLOGY
Disease burden and prevalence

HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce

REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation

PRICING & REIMBURSEMENT

DISTRIBUTION CHANNELS

MARKET ANALYSIS
Projections, product development, manufacturing and trade

COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies

OTC PHARMACEUTICALS

GENERIC PHARMACEUTICALS

BIOLOGICS & BIOSIMILARS

OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis

DIRECTORY

METHODOLOGY & SOURCES

More Pricing reports by Espicom Healthcare Intelligence

The Worldwide Guide to Pricing & Reimbursement by Espicom Healthcare Intelligence
Provides insight into pharmaceutical pricing and reimbursement systems around the world! ...
The Pharmaceutical Market: Vietnam by Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
The Pharmaceutical Market: Venezuela by Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
The Pharmaceutical Market: USA by Espicom Healthcare Intelligence
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting ...
See all reports like this >>

More Norway Pricing reports

Healthcare, Regulatory and Reimbursement Landscape - Norway by GlobalData
Healthcare, Regulatory and Reimbursement Landscape - NorwaySummaryGlobalData, the industry analysis specialist, has released its new report, “Healthcare, Regulatory and Reimbursement Landscape - Norway”. The report ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 1,085  
    Global Site License  USD 7,095  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!